A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Trial Profile

A Randomized Phase 2 Study of AP26113 in Patients With ALK-positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2017

At a glance

  • Drugs Brigatinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALTA
  • Sponsors ARIAD Pharmaceuticals
  • Most Recent Events

    • 16 Oct 2017 Results published in the Takeda Media Release
    • 16 Oct 2017 According to a Takeda media release, data from this trial as of February 21, 2017 will be presented in an oral session at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) 2017.
    • 03 Oct 2017 According to a Takeda media release, the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for ALUNBRIG (brigatinib) 180 mg tablets. Based on data from this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top